Kolltan Pharmaceuticals

Kolltan Pharmaceuticals

Based: New Haven, CT
Raised: $25 million
Investors: HBM Partners AG

The scoop: Kolltan has been developing new oncology therapies based on the scientific work of Yale's Joseph Schlessinger, the co-founder of the company. The biotech has kept a low profile generally, but recently wooed Gerald McMahon, the Senior VP of oncology R&D at MedImmune, into the CEO's job. About 30 staffers are at work at the biotech, which has raised a total of some $75 million. Peter Hirth, the CEO at Plexxikon, sits on the board. The biotech is developing monoclonal antibodies that target receptor tyrosine kinases.

Kolltan Pharmaceuticals

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.